Hyperammonemia and encephalopathy in patients with multiple myeloma

Abstract

American Journal of HematologyVolume 82, Issue 5 p. 414-415 LetterFree Access Hyperammonemia and encephalopathy in patients with multiple myeloma Giampaolo Talamo, Giampaolo Talamo Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorFederica Cavallo, Federica Cavallo Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorMaurizio Zangari, Maurizio Zangari Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorBart Barlogie, Bart Barlogie Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorChoon-Kee Lee, Choon-Kee Lee Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorMauricio Pineda-Roman, Mauricio Pineda-Roman Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorElias Kiwan, Elias Kiwan Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorSomashekar Krishna, Somashekar Krishna Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorGuido Tricot, Guido Tricot Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this author Giampaolo Talamo, Giampaolo Talamo Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorFederica Cavallo, Federica Cavallo Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorMaurizio Zangari, Maurizio Zangari Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorBart Barlogie, Bart Barlogie Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorChoon-Kee Lee, Choon-Kee Lee Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorMauricio Pineda-Roman, Mauricio Pineda-Roman Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorElias Kiwan, Elias Kiwan Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorSomashekar Krishna, Somashekar Krishna Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this authorGuido Tricot, Guido Tricot Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, ArkansasSearch for more papers by this author First published: 28 November 2006 https://doi.org/10.1002/ajh.20808Citations: 23AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Matsuzaki H, Hata H, Sonoki T, et al. Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 1995; 61: 131– 137. 2 Matsuzaki H, Matsuno F, Yoshida M, Hata H, Okazaki K, Takatsuki K. Human myeloma cell line (KHM-4) established from a patient with multiple myeloma associated with hyperammonemia. Intern Med 1992; 31: 339– 343. 3 Otsuki T, Yamada O, Sakaguchi H, et al. In vitro excess ammonia production in human myeloma cell lines. Leukemia 1998; 12: 1149– 1158. 4 Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117: 103– 108. 5 Mathias RS, Kostiner D, Packman S. Hyperammonemia in urea cycle disorders: Role of the nephrologist. Am J Kidney Dis 2001; 37: 1069– 1080. Citing Literature Volume82, Issue5May 2007Pages 414-415 ReferencesRelatedInformation